NEU GRAND LIBRARY
Opening Hours: Monday-Saturday, 08:00-20:00 | E-mail: library@neu.edu.tr
 

You are not logged in Show Basket
  Home     Advanced Search     Back  
Print
Add to Basket
  Brief display     MARC Display     Reserve  
There Might be a Risk of Anaphylaxis Due to Omalizumab (Anti-IgE) Therapy. (Yalçın, A.D.)
Bibliographical information (record 266265)
Help
There Might be a Risk of Anaphylaxis Due to Omalizumab (Anti-IgE) Therapy.
Author:
 Yalçın, A.D. Search Author in Amazon Books

Edition:
 2014.
Classification:
 WF 553
URL:
http://library.neu.edu.tr:2048/login?url=http://dx.doi.org/10.15226/soji/2/2/00116
Detailed notes
    - Omalizumab, a humanized mAb that binds to the CH3 domain, near the binding site for the high-affinity type-I IgE Fc receptors of human IgE, can neutralize free IgE and inhibit the IgE allergic pathway without sensitizing mast cell and basophils. The clinical experience during the patient follow-up of an omalizumab treated severe persistent allergic asthma patient with complicated viral infection is introduced. A female patient (aged 58) with severe persistent allergic asthma, on omalizumab therapy had laryngeal oedema during a complicated common cold infection with bacterial sinusitis after omalizumab injection. Systemic steroids, ketotifen fumarate, antibiotic and antihistamines (desloratadine) were given. We did not stop omalizumab therapy. To our knowledge, this is the first time an association between omalizumab use and laryngeal oedema has been documented. In fact we do not know the exact mechanism behind this relationship.
Related links
Items (1)
Barcode
Status
Library
Section
EOL-981
Item available
NEU Grand LibraryOnline (WF 553 .T44 2014)
Online electronic
NEAR EAST UNIVERSITY GRAND LIBRARY +90 (392) 223 64 64 Ext:5536. Near East Boulevard, Nicosia, TRNC
This software is developed by NEU Library and it is based on Koha OSS
conforms to MARC21 library data transfer rules.